Eurofins Scientific SE Reports Robust FY 2025 Performance Amid Steady Growth

Eurofins Scientific SE (ticker ERFSF.PK) disclosed its full‑year results for 2025 on 29 January 2026, confirming a solid trajectory of earnings expansion, revenue growth, and free‑cash‑flow improvement.

Earnings Momentum

The company posted earnings of EUR 473 million for the year, up from EUR 405 million in 2024. This translates to an earnings‑per‑share (EPS) of EUR 2.23, compared with EUR 1.83 a year earlier—a 24 % increase that aligns with Eurofins’ own guidance. GAAP EPS was reported at EUR 2.31 in the preliminary figures, underscoring the resilience of the core operating model.

Revenue Growth

Revenue reached EUR 7.296 billion, reflecting a 5.0 % year‑over‑year rise from EUR 6.951 billion in 2024. The growth is largely organic, driven by an uptick in contract testing volumes across the company’s 800 laboratories in 47 countries. Eurofins’ diverse service portfolio—spanning agro‑science, biopharma, clinical diagnostics, consumer products, digital testing, and REACH compliance—continues to generate incremental demand.

Margin Expansion

Operating margins expanded modestly, a result of disciplined cost management and a higher mix of high‑margin specialty services. The company’s EBITDA margin widened, reflecting efficient scaling of its global laboratory network and the continued success of its digital testing initiatives.

Cash‑Flow Outlook

Free cash flow has strengthened, bolstered by the company’s ability to generate cash from operations while maintaining a conservative capital‑expenditure profile. Eurofins’ cash‑flow position equips it to pursue strategic acquisitions and shareholder returns without compromising its growth engine.

Share Repurchases and Market Context

In the week of 19–23 January 2026, Eurofins executed a share‑repurchase program, buying shares at a weighted average price of EUR 70.62—the current close on 27 January 2026—while the 52‑week high reached EUR 74.32. The repurchase activity signals management confidence in the stock’s valuation and reinforces shareholder value.

Industry and Macro‑Economic Environment

The European equity landscape remained supportive, with the CAC 40 posting a positive trajectory despite a slightly firmer stance from the U.S. Federal Reserve on interest rates. Eurofins’ performance was therefore achieved in a challenging macro backdrop, underscoring the robustness of its business model.

Forward‑Looking Guidance

Eurofins confirmed its 2027 objectives, reaffirming expectations of continued organic revenue growth, EPS expansion, margin improvement, and higher free‑cash‑flow. The company’s strategic focus on digital testing, contract development and manufacturing organization (CDMO) services, and regulatory compliance services positions it well to capture emerging market opportunities.

Key Takeaway

Eurofins Scientific SE delivers a compelling blend of earnings growth, revenue expansion, and cash‑flow strength, underpinned by a diversified portfolio and global laboratory footprint. Share repurchases, coupled with a supportive market environment, enhance the company’s investment appeal for stakeholders seeking exposure to the life‑sciences tools and services sector.